Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Rifaximin	13
Overall Study	STARTED	Xifaxan	11
Overall Study	STARTED	Placebo	4
Overall Study	Safety Set	Rifaximin	12
Overall Study	Safety Set	Xifaxan	11
Overall Study	Safety Set	Placebo	4
Overall Study	COMPLETED	Rifaximin	11
Overall Study	COMPLETED	Xifaxan	11
Overall Study	COMPLETED	Placebo	3
Overall Study	NOT COMPLETED	Rifaximin	2
Overall Study	NOT COMPLETED	Xifaxan	0
Overall Study	NOT COMPLETED	Placebo	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02920242/flow